Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (41-50 of 228) with videos related to

Pageof 23
Sort By:
Memo|January 7, 2017
Extravasation emergencies: state-of-the-art management and progress in clinical researchUrsula Pluschnig, Werner Haslik, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|February 20, 2018
Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer PatientsLidia Kowalczyk, Rupert Bartsch, Christian F Singer, et al.
Obstetrics and Gynecology|January 25, 2013
Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysisFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphomaStefan Wöhrer, Berthold Streubel, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|August 9, 2017
Biosimilars in the Treatment of Breast CancerMarija Balic, Rupert Bartsch, Thomas Bauernhofer, et al.
Scandinavian Journal of Gastroenterology|November 4, 2005
Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapyStefan Wöhrer, Rupert Bartsch, Michael Hejna, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 4, 2007
HER-2-positive breast cancer: hope beyond trastuzumabRupert Bartsch, Catharina Wenzel, Christoph C Zielinski, et al.
Wiener Medizinische Wochenschrift (1946)|May 18, 2010
Triple-negative breast cancerRupert Bartsch, Reinhard Ziebermayr, Christoph C Zielinski, et al.
Future Oncology (London, England)|February 25, 2014
New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?Peter Birner, Rupert Bartsch, Martin Schreiber, et al.
Breast Care (Basel, Switzerland)|December 5, 2019
Luminal Metastatic Breast CancerJens Huober, Rupert Bartsch, Frederik Marmé, et al.
Pageof 23

Showing results (41-50 of 228) with videos related to

Sort By:
Pageof 23
Memo|January 7, 2017
Extravasation emergencies: state-of-the-art management and progress in clinical researchUrsula Pluschnig, Werner Haslik, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|February 20, 2018
Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer PatientsLidia Kowalczyk, Rupert Bartsch, Christian F Singer, et al.
Obstetrics and Gynecology|January 25, 2013
Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysisFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphomaStefan Wöhrer, Berthold Streubel, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|August 9, 2017
Biosimilars in the Treatment of Breast CancerMarija Balic, Rupert Bartsch, Thomas Bauernhofer, et al.
Scandinavian Journal of Gastroenterology|November 4, 2005
Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapyStefan Wöhrer, Rupert Bartsch, Michael Hejna, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 4, 2007
HER-2-positive breast cancer: hope beyond trastuzumabRupert Bartsch, Catharina Wenzel, Christoph C Zielinski, et al.
Wiener Medizinische Wochenschrift (1946)|May 18, 2010
Triple-negative breast cancerRupert Bartsch, Reinhard Ziebermayr, Christoph C Zielinski, et al.
Future Oncology (London, England)|February 25, 2014
New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?Peter Birner, Rupert Bartsch, Martin Schreiber, et al.
Breast Care (Basel, Switzerland)|December 5, 2019
Luminal Metastatic Breast CancerJens Huober, Rupert Bartsch, Frederik Marmé, et al.
Pageof 23